These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9927564)

  • 1. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantalization of continuous data for benchmark dose estimation.
    Gaylor DW
    Regul Toxicol Pharmacol; 1996 Dec; 24(3):246-50. PubMed ID: 8975754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
    Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
    Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice.
    Platzek T; Bochert G
    Teratog Carcinog Mutagen; 1996; 16(3):169-81. PubMed ID: 8983119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of excursions above the ADI: duration in relation to pivotal studies.
    Walker R
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S114-8. PubMed ID: 10597624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculation of benchmark doses from teratology data.
    Auton TR
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):152-67. PubMed ID: 8041913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the standard deviation in the estimation of benchmark doses with continuous data.
    Gaylor DW; Slikker W
    Risk Anal; 2004 Dec; 24(6):1683-7. PubMed ID: 15660621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S79-86. PubMed ID: 10597618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental toxicity evaluation of emodin in rats and mice.
    Jahnke GD; Price CJ; Marr MC; Myers CB; George JD
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):89-101. PubMed ID: 15098202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A probabilistic framework for non-cancer risk assessment.
    Chen JJ; Moon H; Kodell RL
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental and reproductive toxicity evaluation of toluene vapor in the rat II. Developmental toxicity.
    Roberts LG; Nicolich MJ; Schreiner CA
    Reprod Toxicol; 2007 Jun; 23(4):521-31. PubMed ID: 17360154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.